Pulse of Asia 2022

Speaker's biography and Meeting abstract

Xinli LI MD./PhD. 
supervisor, chief physician of 
The First Affiliated Hospital of Nanjing Medical University
Xinli LI (1957~), MD./PhD. supervisor, chief physician of the First Affiliated Hospital of Nanjing Medical University. He has dedicted in the basic and clinical research on coronary heart disease, difficult cardiovascular disease, and heart failure since 1983. He is the chairman of various groups in Chinese Medical Association. He chaired and held in several "National Natural Science Foundation of China" Project, and participated in developing guidelines and expert consensus in different cardiovascular diseases such as the expert consensus on the prevention and diagnosis of infective endocarditis, Chinese heart failure diagnosis and treatment guideline 2018, etc.


Meeting abstract

Lecture title:
Real-world analysis of ARNi Usage in Chinese HFrEF Patients
Xinli Li, Iokfai Cheang
The First Affiliated Hospital of Nanjing Medical University, China

Background: Study aims to investigate the dosage pattern, efficacy, and safety of Sacubitril/Valsartan (Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding real-world setting.
Methods: Patients from 27 centers with a confirmed diagnosis of HFrEF and initiated Sac/Val treatment were enrolled. Primary objective was to evaluate the dosage pattern and change of heart failure status.
Results: In final cohort of 983 patients, outpatient Sac/Val treatment demonstrated a similar beneficial effect in NT-proBNP and cardiac function. After initiating treatment, overall and sub-population showed similar safety and efficacy. Patients who received higher dose of Sac/Val (>200mg/d) demonstrated a better improvement in LV function and reduction of NT-proBNP regardless of adjustment.
Conclusion: Among Chinese HFrEF patients, Sac/Val showed a comparable reduction in NT-proBNP and improvement in cardiac function. Data further support guideline recommendations of Sac/Val in Chinese population. Optimal up-titration might provide further benefits. Further long-term and prognostic studies are needed.